Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.

In preclinical studies, a B-Raf inhibitor called WYE-130600 caused dose-related skin effects in dogs and rats, suggesting potential similar responses might occur in humans.

This paper reviews finasteride's role and efficacy in treating male pattern hair loss, finding significant improvements in hair growth and density with a favorable safety profile, though some side effects were noted.

In this case study, oral folic acid therapy resulted in noticeable improvement and eventual recovery from hair loss and skin issues in a three-week-old Charolais calf.

This study found that hair growth was maintained in alopecic sites using scalp autografts with triamcinolone acetonide, but homografts were typically rejected.

Finasteride may lower depression risk in younger men with hair loss but increase it in older men with prostate issues.

This study found that combining carboxytherapy with standard treatment for androgenetic alopecia in men significantly improved clinical outcomes and patient satisfaction compared to standard treatment alone over a 24-week period.

This study reviewed human evidence on the effects of 5α-reductase inhibitors, finasteride and dutasteride, on semen parameters and gonadotrophins, finding finasteride causes mild, reversible changes, while dutasteride may lead to more pronounced and potentially less reversible impacts, suggesting caution for those planning to conceive.

This study developed a testosterone propionate-induced C57BL/6 mouse model of androgenetic alopecia, demonstrating that high-dose, prolonged testosterone administration inhibited hair regrowth and mirrored human AGA pathology, providing a useful platform for studying hair loss mechanisms and testing therapies targeting the Wnt/β-catenin pathway.

This study investigated the integration of crystal engineering and microneedle technology for androgenetic alopecia treatment, finding that microneedles loaded with newly developed Kopexil multicomponent crystals reduced drug diffusion rates in vitro compared to standard formulations.

In these aquatic laboratory studies, researchers found that Finasteride reduced dihydrotestosterone levels in fathead minnows and increased gene expression related to androgen pathways in both minnows and medaka, indicating potential conservation of pharmaceutical effects on androgen biosynthesis across different species.

This review identified emerging therapies for androgenetic alopecia, such as low-dose oral minoxidil and stem cell-based treatments, which show promise for improved hair loss management but require standardized protocols and large-scale trials for further validation.

In this study, a newly developed polyherbal hair oil exhibited promising characteristics, including a beneficial pH and antimicrobial activity against Staphylococcus aureus, with preliminary tests suggesting it supports scalp and hair health without adverse effects.

This study found that a catechins-rich Assam tea extract demonstrated antioxidant effects and hair growth promotion in mice, suggesting its potential as a natural alternative for treating hair loss.

This study developed an ultrahigh-power sonicator to improve protein extraction from hair shafts, followed by advanced proteomic analysis, identifying 239 differentially expressed proteins in fetal growth restriction cases compared to healthy controls, which were validated as potential biomarkers for perinatal diagnostics.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This systematic review and meta-analysis found that low-dose minoxidil treatment effectively enhances facial hair development with relatively minimal side effects, which can be beneficial in primary care settings.

This systematic review and meta-analysis found that platelet-rich plasma (PRP) therapy is effective in increasing hair density and reducing hair loss for alopecia, with variations in response based on activation status.

Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.

This study reports that low-dose oral minoxidil is generally well tolerated from a cardiovascular perspective, and serious side effects like pericardial effusion are associated with higher doses and pre-existing conditions.

In this study, oral minoxidil treatment significantly increased serum VEGF levels and improved hair growth measures compared to a control group, suggesting its potential as an effective approach for promoting hair regrowth in androgenetic alopecia.

This study found that 18-β-Glycyrrhetinic acid, a licorice component, stimulated human hair follicle cell proliferation, inhibited testosterone 5α-reductase, and suppressed TGF-β1, suggesting potential for treating androgenetic alopecia by promoting hair growth and prolonging the anagen phase.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

Low vitamin C caused bleeding and corkscrew hair, resolved with vitamin C treatment.

In this study, women with androgenetic alopecia underwent stem cell treatment, which led to significant improvements in sexual arousal and satisfaction, psychological health, and environmental quality of life, but not in physical health or social relationships after six months.

This study involved a Delphi-method consensus from 34 Spanish dermatologists, outlining structured recommendations for managing androgenetic alopecia based on available scientific evidence and expert opinions, aiming to guide clinical practice amid limited treatment approvals and varying effectiveness.

The authors concluded that the concept of postfinasteride syndrome remains contentious and may be more plausibly characterized as a psychiatric condition rather than a consistent medical syndrome.

This study found that male patients with androgenetic alopecia had higher serum levels of Zinc Alpha 2 Glycoprotein than healthy controls, suggesting its potential role in the disease's pathophysiology.

In this case report, a 35-year-old man with androgenetic alopecia showed significant improvement in hair thickness and density after six months of conservative therapy with topical minoxidil, oral finasteride, and a gel with oligopeptides, caffeine, and taurine.

This study evaluated low dose oral minoxidil as a treatment for female pattern hair loss but reports no new clinical results.